Stone man syndrome, formally called fibrodysplasia ossificans progressiva (FOP), is caused by a mutation in a single gene that turns the body’s injury-repair signals into triggers for new bone growth. Soft tissues like muscles, tendons, and ligaments gradually transform into solid bone, locking joints in place and restricting movement over a lifetime. It affects roughly 1 in every 1.14 million people, making it one of the rarest genetic conditions known.
The Gene Behind the Disease
FOP traces back to a mutation in a gene called ACVR1, which provides instructions for building a receptor on the surface of cells. This receptor is part of a signaling network that uses bone morphogenetic proteins (BMPs) to regulate bone and cartilage growth. In about 97% of FOP cases, the exact same mutation occurs: a single amino acid swap at position 206 in the receptor’s structure, where arginine is replaced by histidine.
That one change rewires how the receptor interprets incoming signals. Normally, a molecule called activin A lands on this receptor and blocks bone-growth signaling. It acts as a natural brake. But the mutated receptor reads activin A as a green light instead, activating the same bone-building pathway that BMPs use. The receptor also retains its normal ability to respond to BMPs, so the system is essentially running with no brakes and a stuck accelerator. This is what researchers describe as a “gain of function” mutation: the receptor doesn’t just malfunction, it gains an entirely new, destructive capability.
How Soft Tissue Turns Into Bone
When the mutated receptor receives a signal (whether from BMPs or from activin A acting as a false trigger), it sets off a chain reaction inside the cell. The receptor activates proteins called Smads, which travel into the cell’s nucleus and switch on genes that direct the cell to build bone. This is the same pathway the body uses to form your skeleton before birth, but in FOP it reactivates in places where bone should never exist.
One of the most striking discoveries is that the cells lining blood vessels can be a direct source of this misplaced bone. Research has shown that up to 50% of the abnormal cartilage and bone in FOP patients originates from cells in the walls of blood vessels. Under the influence of the overactive receptor, these endothelial cells transform into stem cell-like cells that can then become cartilage or bone cells. This process, called endothelial-to-mesenchymal transition, helps explain why new bone can appear in so many different soft tissues throughout the body.
What Triggers Flare-Ups
The genetic mutation is present from birth, but FOP doesn’t produce a steady, continuous stream of new bone. Instead, it progresses through flare-ups, episodes of painful soft-tissue swelling that often result in new bone formation. These flare-ups are set off by physical trauma of almost any kind: a fall, a surgery, a broken bone, or even a viral illness like the flu. Intramuscular injections (where a needle enters muscle tissue) are a well-known trigger, which is why people with FOP are advised to receive vaccines as subcutaneous injections into the fatty layer of skin instead.
The connection between trauma and bone growth makes the disease uniquely cruel. Attempts to surgically remove the extra bone reliably trigger even more bone formation at the surgical site. Biopsies of suspicious lumps, a standard diagnostic step for many conditions, can provoke the same response. Nearly 90% of FOP patients worldwide are initially misdiagnosed, and roughly two-thirds undergo unnecessary diagnostic procedures that can worsen their condition.
How the Disease Progresses
FOP follows a remarkably consistent pattern through the body. It typically begins near the neck and spine, then moves outward: shoulders, then elbows, hips, knees, wrists, ankles, and finally the jaw. This progression from the central skeleton toward the limbs mirrors the developmental patterns seen in embryonic bone formation.
The earliest and most reliable physical sign appears at birth, well before any extra bone develops. Nearly all people with FOP are born with characteristic malformations of the big toes: both toes angle inward (a condition called hallux valgus), and the joint at the tip of the toe is either fused or missing entirely. This toe abnormality is so closely linked to FOP that it can prompt a correct diagnosis years before the first flare-up, potentially sparing a child from harmful biopsies or surgeries.
Life Expectancy and Cause of Death
FOP significantly shortens lifespan. One study of 60 deceased patients found a median age at death of 40 years, though the range was wide, from 3 to 77. When researchers combined data from both living and deceased individuals in the international FOP community (431 people total), the estimated median lifespan was 56 years.
The primary killer is respiratory failure. As bone forms across the rib cage and spine, the chest wall loses its ability to expand and contract normally, a condition called thoracic insufficiency syndrome. This accounted for 54% of deaths, at a median age of 42. Pneumonia caused another 15% of deaths, and complications from falls (themselves made more dangerous by the inability to brace or catch oneself) accounted for 11%.
Treatment Options
For decades, there was no approved treatment for FOP. That changed when the FDA approved palovarotene (brand name Sohonos) as the first drug specifically indicated for the condition. It’s approved for adults and children aged 8 and older for females and 10 and older for males. The drug works by reducing the volume of new bone that forms. Patients take a low daily dose, with a higher dose for 12 weeks during flare-ups.
A second approach targets the root mechanism more directly. Because the mutated receptor’s response to activin A is the core driver of the disease, researchers developed garetosmab, an antibody that binds activin A and blocks it from reaching the receptor. In a phase 2 trial, garetosmab substantially reduced both new bone formation and the inflammatory flare-ups that precede it. A phase 3 trial is currently underway, along with planned studies in children. Five deaths occurred during the phase 2 study in patients with advanced disease, though a definitive link to the drug was not established.
Beyond medication, managing FOP is largely about prevention: avoiding trauma, adapting daily life to minimize fall risk, choosing subcutaneous over intramuscular injections, and taking precautions against viral infections that can spark flare-ups.